What is the P/E ratio for Viatris Inc. (VTRS)?

The P/E ratio for VTRS stock is N/A.

What is the TTM average P/E ratio for Viatris Inc. (VTRS)?

The TTM average P/E ratio for VTRS stock is 6.70.

What is the 3Y average P/E ratio for Viatris Inc. (VTRS)?

The 3Y average P/E ratio for VTRS stock is 11.06.

What is the 5Y average P/E ratio for Viatris Inc. (VTRS)?

The 5Y average P/E ratio for VTRS stock is 94.30.

What is the 10Y average P/E ratio for Viatris Inc. (VTRS)?

The 10Y average P/E ratio for VTRS stock is 29.93.

Viatris Inc. (VTRS)

Compare

Viatris Inc. (VTRS) PE Ratio: N/A

The P/E ratio for Viatris Inc. (VTRS) is N/A as of Sunday, June 21, 2026.

PEG Ratio|P/B Ratio|EPS|All Metrics

VTRS PE Ratio Chart

VTRS PE Ratio

295.25+4624.00% 1Y

Zoom

VTRS Average PE Ratio Chart

VTRS PE Ratio Metrics

PE RATIO

N/A

PE RATIO AVG TTM

6.70

PE RATIO AVG 3Y

11.06

PE RATIO AVG 5Y

94.30

PE RATIO AVG 10Y

29.93

PE RATIO AVG 15Y

N/A

PE RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

N/A

CURRENT VS 3Y AVG

N/A

CURRENT VS 5Y AVG

N/A

CURRENT VS 10Y AVG

N/A

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

VTRS Competitors' PE Ratio

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Viatris Inc. (VTRS)	$17.90B	N/A	6.70	11.06	94.30
Zimmer Biomet Holdings, Inc. (ZBH)vs ›	$17.02B	22.85	23.48	29.91	47.60
Hologic, Inc. (HOLX)vs ›	$16.97B	31.67	28.12	30.08	22.83
Incyte Corporation (INCY)vs ›	$19.62B	13.87	37.94	113.26	79.84
Labcorp Holdings Inc. (LH)vs ›	$20.98B	22.66	27.08	32.19	23.44
DaVita Inc. (DVA)vs ›	$13.34B	20.92	14.57	15.88	14.84
Medpace Holdings, Inc. (MEDP)vs ›	$13.14B	28.91	33.95	33.23	33.11
Solventum Corporation (SOLV)vs ›	$13.06B	9.23	18.38	17.00	17.00
Align Technology, Inc. (ALGN)vs ›	$13.04B	30.55	29.21	42.52	47.46
United Therapeutics Corporation (UTHR)vs ›	$22.78B	19.84	17.21	14.96	16.04

P/E Comparison

Trailing P/E

N/A

Forward P/E

6.2

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$15.37

Forward EPS (Est.)

$2.47

Forward P/E

6.23

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

Viatris Inc. PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Viatris Inc. PE Ratio FAQ

What is the P/E ratio for Viatris Inc. (VTRS)?: The P/E ratio for VTRS stock is N/A.
What is the TTM average P/E ratio for Viatris Inc. (VTRS)?: The TTM average P/E ratio for VTRS stock is 6.70.
What is the 3Y average P/E ratio for Viatris Inc. (VTRS)?: The 3Y average P/E ratio for VTRS stock is 11.06.
What is the 5Y average P/E ratio for Viatris Inc. (VTRS)?: The 5Y average P/E ratio for VTRS stock is 94.30.
What is the 10Y average P/E ratio for Viatris Inc. (VTRS)?: The 10Y average P/E ratio for VTRS stock is 29.93.

Viatris Inc. PE Ratio History

DATE	PE RATIO
2024-05-08	295.25
2024-05-07	293.00
2024-05-06	295.50
2024-05-03	294.50
2024-05-02	290.00
2024-05-01	290.75
2024-04-30	289.25
2024-04-29	294.50
2024-04-26	289.25
2024-04-25	286.75
2024-04-24	288.75
2024-04-23	284.00
2024-04-22	281.25
2024-04-19	281.25
2024-04-18	278.00
2024-04-17	277.50
2024-04-16	278.00
2024-04-15	283.00
2024-04-12	283.25
2024-04-11	289.25
2024-04-10	292.75
2024-04-09	295.50
2024-04-08	293.75
2024-04-05	295.00
2024-04-04	294.00
2024-04-03	300.50
2024-04-02	298.50
2024-04-01	298.50
2024-03-28	298.50
2024-03-27	295.75
2024-03-26	290.00
2024-03-25	295.75
2024-03-22	296.00
2024-03-21	300.25
2024-03-20	297.00
2024-03-19	296.75
2024-03-18	294.00
2024-03-15	298.50
2024-03-14	295.50
2024-03-13	301.25
2024-03-12	301.50
2024-03-11	299.25
2024-03-08	306.50
2024-03-07	308.25
2024-03-06	305.00
2024-03-05	307.00
2024-03-04	309.00
2024-03-01	314.75
2024-02-29	309.25
2024-02-28	307.25
2024-02-27	330.75
2024-02-26	335.75
2024-02-23	8.96
2024-02-22	8.85
2024-02-21	8.78
2024-02-20	8.77
2024-02-16	8.65
2024-02-15	8.49
2024-02-14	7.99
2024-02-13	7.93
2024-02-12	7.91
2024-02-09	7.74
2024-02-08	7.66
2024-02-07	7.77
2024-02-06	7.87
2024-02-05	7.67
2024-02-02	7.85
2024-02-01	7.86
2024-01-31	7.79
2024-01-30	7.82
2024-01-29	7.87
2024-01-26	7.90
2024-01-25	7.77
2024-01-24	7.76
2024-01-23	7.79
2024-01-22	7.71
2024-01-19	7.55
2024-01-18	7.46
2024-01-17	7.59
2024-01-16	7.78
2024-01-12	7.74
2024-01-11	7.99
2024-01-10	8.01
2024-01-09	7.68
2024-01-08	7.75
2024-01-05	7.93
2024-01-04	7.65
2024-01-03	7.53
2024-01-02	7.54
2023-12-29	7.17
2023-12-28	7.19
2023-12-27	7.13
2023-12-26	7.09
2023-12-22	7.05
2023-12-21	7.05
2023-12-20	6.92
2023-12-19	6.88
2023-12-18	6.69
2023-12-15	6.80
2023-12-14	6.88
2023-12-13	6.71
2023-12-12	6.54
2023-12-11	6.51
2023-12-08	6.51
2023-12-07	6.46
2023-12-06	6.42
2023-12-05	6.36
2023-12-04	6.41
2023-12-01	6.21
2023-11-30	6.08
2023-11-29	6.05
2023-11-28	6.05
2023-11-27	6.19
2023-11-24	6.25
2023-11-22	6.21
2023-11-21	6.21
2023-11-20	6.27
2023-11-17	6.26
2023-11-16	6.07
2023-11-15	6.20
2023-11-14	6.11
2023-11-13	5.93
2023-11-10	6.09
2023-11-09	6.00
2023-11-08	6.11
2023-11-07	6.05
2023-11-06	6.02
2023-11-03	6.06
2023-11-02	5.84
2023-11-01	5.83
2023-10-31	5.82
2023-10-30	5.78
2023-10-27	5.73
2023-10-26	5.88
2023-10-25	5.86
2023-10-24	5.95
2023-10-23	5.83
2023-10-20	6.08
2023-10-19	6.08
2023-10-18	6.12
2023-10-17	6.16
2023-10-16	6.19
2023-10-13	6.10
2023-10-12	6.18
2023-10-11	6.33
2023-10-10	6.29
2023-10-09	6.31
2023-10-06	6.31
2023-10-05	6.33
2023-10-04	6.34
2023-10-03	6.31
2023-10-02	6.57
2023-09-29	6.44
2023-09-28	6.41
2023-09-27	6.27
2023-09-26	6.35
2023-09-25	6.35
2023-09-22	6.30
2023-09-21	6.33
2023-09-20	6.46
2023-09-19	6.46
2023-09-18	6.42
2023-09-15	6.39
2023-09-14	6.42
2023-09-13	6.37
2023-09-12	6.45
2023-09-11	6.54
2023-09-08	6.61
2023-09-07	6.54
2023-09-06	6.61
2023-09-05	6.94
2023-09-01	7.05
2023-08-31	7.03
2023-08-30	7.19
2023-08-29	7.19
2023-08-28	7.16
2023-08-25	7.17
2023-08-24	7.16
2023-08-23	7.19
2023-08-22	7.29
2023-08-21	7.35
2023-08-18	7.36
2023-08-17	7.41
2023-08-16	7.32
2023-08-15	7.29
2023-08-14	7.31
2023-08-11	7.42
2023-08-10	7.29
2023-08-09	7.36
2023-08-08	7.29
2023-08-07	7.19
2023-08-04	6.75
2023-08-03	6.66
2023-08-02	6.64
2023-08-01	6.51
2023-07-31	6.71
2023-07-28	6.62
2023-07-27	6.58
2023-07-26	6.68
2023-07-25	6.63
2023-07-24	6.76
2023-07-21	6.68
2023-07-20	6.67
2023-07-19	6.64
2023-07-18	6.48
2023-07-17	6.38
2023-07-14	6.47
2023-07-13	6.55
2023-07-12	6.52
2023-07-11	6.53
2023-07-10	6.32
2023-07-07	6.28
2023-07-06	6.27
2023-07-05	6.31
2023-07-03	6.30
2023-06-30	6.36
2023-06-29	6.31
2023-06-28	6.19
2023-06-27	6.27
2023-06-26	6.27
2023-06-23	6.22
2023-06-22	6.40
2023-06-21	6.44
2023-06-20	6.49
2023-06-16	6.55
2023-06-15	6.33
2023-06-14	6.22
2023-06-13	6.13
2023-06-12	5.99
2023-06-09	5.97
2023-06-08	6.06
2023-06-07	6.18
2023-06-06	6.06
2023-06-05	5.94
2023-06-02	5.94
2023-06-01	5.85
2023-05-31	5.83
2023-05-30	5.85
2023-05-26	5.80
2023-05-25	5.75
2023-05-24	5.75
2023-05-23	5.89
2023-05-22	6.03
2023-05-19	5.94
2023-05-18	5.97
2023-05-17	5.92
2023-05-16	5.83
2023-05-15	5.97
2023-05-12	5.91
2023-05-11	5.96
2023-05-10	6.11
2023-05-09	6.20
2023-05-08	6.25
2023-05-05	5.43
2023-05-04	5.27
2023-05-03	5.35
2023-05-02	5.33
2023-05-01	5.47
2023-04-28	5.46
2023-04-27	14.03

Showing the most recent 260 of 2,181 data points. The chart above shows the full history.

Related Metrics

PEG Ratio P/B Ratio EPS All Metrics

See the Lowest P/E Ratio Stocks ranking →

About Viatris Inc.

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.

Canonsburg, PA

32,000 employees

www.viatris.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Scott Andrew Smith

View full financials